- UK scientists at Oxford are developing a vaccine for the rare Bundibugyo Ebola strain
- The vaccine uses modified chimpanzee cold virus technology from the COVID-19 vaccine
- Animal trials are in progress, with human trials possible within two to three months
Scientists in the UK are working to create a vaccine against the Bundibugyo strain of Ebola, a rare version of the virus linked to the recent outbreak in Central Africa. Unlike the other strain, Zaire, which already has approved vaccines, Bundibugyo does not yet have a licensed vaccine or treatment. Researchers at Oxford University are developing the novel jab targeting the rare strain. The World Health Organization says clinical trials could begin in just two to three months if animal tests go well.
This breakthrough uses the same technology the Oxford team created during the COVID-19 pandemic. The vaccine employs a harmless chimpanzee cold virus modified to carry Bundibugyo genetic information, teaching the immune system to recognise and fight real Ebola without causing infection. Animal trials are already underway, though scientists caution there's no guarantee of success until human testing begins. The Serum Institute of India stands ready to mass-produce the vaccine once Oxford provides the medical-grade materials needed.
How The Vaccine Works
The ChAdOx1 technology is versatile. During the pandemic, scientists loaded it with COVID virus genetic blueprints. Now, they've swapped in Bundibugyo Ebola genetic information. The modified cold virus delivers this genetic code to human cells, which then produce harmless Ebola proteins. This trains the immune system to spot and destroy actual Ebola virus if someone gets infected later.
This approach is faster than traditional vaccine development because the basic platform already exists and has proven to be safe. Scientists don't need to start from scratch, they simply reprogram the delivery system for a different disease.
What Happens Next
The next stage involves testing, safety checks, and possible emergency use planning. Scientists must confirm that the vaccine creates strong protection and does not cause serious side effects. Even with fast progress, careful evaluation remains essential.
The work under way in the UK reflects a broader lesson from recent health emergencies: preparation matters. A vaccine ready within months would not only help control the current outbreak but could also improve global readiness for future Ebola threats.
Why This Ebola Strain Is Different
Ebola is not a single virus. Scientists have identified several species, and vaccines that are already available mainly target the Zaire strain. The Bundibugyo version has caused fewer outbreaks in the past, so it received less attention. Because of this, the world entered the latest outbreak without a ready-made vaccine.
Experts say this gap in preparation is now driving urgent action. Researchers are examining different vaccine designs, including viral-vector methods and approaches based on technology used during earlier epidemic responses. The aim is to create protection that specifically targets the Bundibugyo strain while remaining safe for human use.
Why This Matters Now
The Bundibugyo strain is particularly dangerous because no approved vaccine exists for it. Current Ebola vaccines only protect against other strains like Zaire. With outbreaks occurring and the strain killing roughly 33% of infected people, rapid vaccine development could save countless lives.
Another experimental Bundibugyo vaccine is in development but won't be ready for trials for six to nine months, making Oxford's faster timeline crucial. If successful, this vaccine could become a vital tool in stopping future Ebola outbreaks before they spread widely. The speed of this development shows how pandemic-era vaccine science can be rapidly redirected to fight other deadly diseases, offering hope for quicker responses to emerging health threats.
Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.
